P

Protalix Biotherapeutics Inc
AMEX:PLX

Watchlist Manager
Protalix Biotherapeutics Inc
AMEX:PLX
Watchlist
Price: 2.105 USD 1.69%
Market Cap: 169.3m USD

Operating Margin

13.3%
Current
Improving
by 15.2%
vs 3-y average of -1.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
13.3%
=
Operating Income
$8.2m
/
Revenue
$61.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
13.3%
=
Operating Income
$8.2m
/
Revenue
$61.9m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Protalix Biotherapeutics Inc
AMEX:PLX
165.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.6B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.7B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
67th
Based on 14 112 companies
67th percentile
13.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Protalix Biotherapeutics Inc
Glance View

Market Cap
169.3m USD
Industry
Biotechnology

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 193 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.

PLX Intrinsic Value
3.311 USD
Undervaluation 36%
Intrinsic Value
Price
P
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
13.3%
=
Operating Income
$8.2m
/
Revenue
$61.9m
What is Protalix Biotherapeutics Inc's current Operating Margin?

The current Operating Margin for Protalix Biotherapeutics Inc is 13.3%, which is above its 3-year median of -1.9%.

How has Operating Margin changed over time?

Over the last 3 years, Protalix Biotherapeutics Inc’s Operating Margin has increased from -33% to 13.3%. During this period, it reached a low of -38.9% on Jun 30, 2024 and a high of 21.3% on Sep 30, 2023.

Back to Top